melperone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tranquillizers, neuroleptics, 4'-fluoro-4-piperidinobutyrophenone derivatives 1677 3575-80-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • melperone
  • flubuperone
  • methylperone
  • Molecular weight: 263.36
  • Formula: C16H22FNO
  • CLOGP: 3.88
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 20.31
  • ALOGS: -3.73
  • ROTB: 5

Drug dosage:

DoseUnitRoute
0.30 g O
0.30 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 21.70 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 14 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 46 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1972 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Congenital absence of bile ducts 97.54 93.76 9 61 8 2358007

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC N05AD03 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Butyrophenone derivatives

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.28 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 2C GPCR Ki 5.68 PDSP
5-hydroxytryptamine receptor 1D GPCR Ki 5.47 PDSP
5-hydroxytryptamine receptor 1A GPCR Ki 5.66 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 5.36 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 5.62 PDSP
D(4) dopamine receptor GPCR Ki 6.39 WOMBAT-PK
Cytochrome P450 2D6 Enzyme WOMBAT-PK
Histamine H1 receptor GPCR Ki 6.24 WOMBAT-PK
D(3) dopamine receptor GPCR Ki 7.06 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 6.74 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR Ki 6.72 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 6.82 WOMBAT-PK
D(2) dopamine receptor GPCR Ki 6.98 WOMBAT-PK

External reference:

IDSource
C0066477 UMLSCUI
D07309 KEGG_DRUG
441821005 SNOMEDCT_US
442519006 SNOMEDCT_US
29961 RXNORM
006742 NDDF
J8WA3K39B7 UNII
2070 INN_ID
DB09224 DRUGBANK_ID
15387 PUBCHEM_CID
CHEMBL1531134 ChEMBL_ID

Pharmaceutical products:

None